NCT04745390 Standard Versus Radiobiologically-Guided Dose Selected SBRT in Liver Cancer
| NCT ID | NCT04745390 |
| Status | Recruiting |
| Phase | — |
| Sponsor | London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's |
| Condition | Hepatocellular Carcinoma |
| Study Type | INTERVENTIONAL |
| Enrollment | 110 participants |
| Start Date | 2021-08-01 |
| Primary Completion | 2026-04 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
This trial targets 110 participants in total. It began in 2021-08-01 with a primary completion date of 2026-04.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
Radiation is a standard treatment option for patients with liver cancer. Unfortunately, the tumour grows after radiation in many patients and radiation can harm normal tissues. A new treatment using a specialized radiation procedure called Stereotactic body radiotherapy (SBRT) may increase the chance to control liver cancer and reduce the chance of harm to normal tissues. SBRT allows radiation treatments to be focused more precisely, and be delivered more accurately than with older treatments. SBRT has become a routine treatment. Further research has found that specialized computer programs can possibly guide the selection of an appropriate SBRT dose. This is called radiobiological guidance. However, this has not yet been proven to improve outcomes and/or reduce toxicity. Therefore, the purpose of this study is to find out if SBRT at standard dose versus SBRT guided by radiobiological techniques is better for you and your liver cancer.
Eligibility Criteria
Inclusion Criteria: 1. Eligible patients include patients with any of the following: * Primary hepatobiliary cancer confirmed pathologically or, * Non-lymphoma liver metastases confirmed pathologically or, * Radiographic liver lesions most consistent with metastases, in a patient with known pathologically proven non-lymphoma cancer and a previously negative CT or MRI of the liver or, * Hepatocellular carcinoma diagnosed with vascular enhancement of the lesion consistent with hepatocellular carcinoma, and with an elevated AFP, in the setting of cirrhosis or chronic hepatitis. 2. ≤ 5 liver lesions measurable on a contrast-enhanced liver CT or MRI performed within 90 days prior to study entry. 3. Primary liver lesion or liver metastases measuring ≤ 25 cm. 4. Extrahepatic cancer is permitted if liver involvement is judged to be life-limiting 5. No contraindications to radiotherapy 6. Patient must be judged medically or surgically unresectable 7. Zubrod Performance Scale = 0-3 8. Age \> 18 9. Systemic treatment including multikinase inhibitors and immunotherapy are allowed. Multikinase inhibitors must be held 2 weeks prior to radiation and may be restarted 1 week post radiation. 10. Previous liver resection or ablative therapy is permitted 11. Chemotherapy must be completed at least 2 weeks prior to radiation therapy and not planned to be administered for at least 1 week (for anthracyclines at least 4 weeks) after completion of treatment. 12. Life expectancy \> 6 months. 13. Women of childbearing potential and male participants must practice adequate contraception. Exclusion Criteria: 1. Severe cirrhosis or liver failure defined as Child Pugh \>B7 2. Prior radiotherapy to the region of the study cancer that would result in overlap of radiation therapy fields 3. Severe, active co-morbidity, defined as limiting the patient's life to less than 6 months 4. Active hepatitis or clinically significant liver failure. Treated hepatitis is permitted. 5. Pregnancy, nursing women, or women of childbearing potential, and men who are sexually active and not willing/able to use medically acceptable forms of contraception; this exclusion is necessary because the treatment involved in this study may be teratogenic.
Contact & Investigator
Michael Lock, MD
PRINCIPAL INVESTIGATOR
London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's
Frequently Asked Questions
Who can join the NCT04745390 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, studying Hepatocellular Carcinoma. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT04745390 currently recruiting?
Yes, NCT04745390 is actively recruiting participants. Contact the research team at morgan.black@lhsc.on.ca for enrollment information.
Where is the NCT04745390 trial being conducted?
This trial is being conducted at London, Canada.
Who is sponsoring the NCT04745390 clinical trial?
NCT04745390 is sponsored by London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's. The principal investigator is Michael Lock, MD at London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's. The trial plans to enroll 110 participants.
Related Trials
Related Intelligence Guides
In-depth guides covering this condition's trials, eligibility, and what to expect.